Biotech Values

[DewDiligence]

VRUS—Do you think Roche will bring the PROPEL study (RG7128+SOC Genotype 1&4) into phase 3?

It depends on how quickly Roche can complete the longer (24-week) phase-2b study, which started enrolling patients in Feb 2010, and on the data from competing HCV programs that are released by the time that study is completed.

I consider Roche’s decision to run a second phase-2b in geno-1/4 patents somewhat bearish for RG7128 insofar as Roche could have opted to go directly to phase-3 after upon completion of the 12-week phase-2b study.